论文部分内容阅读
目的探讨大、小剂量厄贝沙坦治疗糖尿病肾病的临床疗效。方法 27例糖尿病肾病患者给予大剂量厄贝沙坦(0.3g/d)口服,另25例给予小剂量厄贝沙坦(0.15g/d)口服,治疗2个月后观察两组尿蛋白排泄率、血肌酐及血钾的变化。结果大剂量组治疗后尿蛋白排泄率显著下降,下降幅度大于小剂量组,差异有统计学意义(P<0.05);但在血肌酐及血钾方面,两组的下降水平无统计学差异(P>0.05),结论大剂量厄贝沙坦可显著改善糖尿病肾病尿蛋白,且无明显副作用。
Objective To investigate the clinical efficacy of large and small doses of irbesartan in the treatment of diabetic nephropathy. Methods Twenty-seven patients with diabetic nephropathy were orally administered with high dose irbesartan (0.3g / d) and the other 25 patients given low dose irbesartan (0.15g / d) orally. After 2 months of treatment, urinary protein excretion Rate, serum creatinine and serum potassium changes. Results The urinary protein excretion rate of the high-dose group was significantly lower than that of the low-dose group (P <0.05), but there was no significant difference in the serum creatinine and serum potassium between the two groups P> 0.05), Conclusion High-dose Irbesartan can significantly improve diabetic nephropathy urinary protein, and no significant side effects.